Non-Executive Director Change

RNS Number : 8793I

Novacyt S.A.

07 December 2022

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Non-Executive Director Change

Paris, France and Eastleigh, UK - 7 Dec 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Edwin Snape has informed the Board that he wishes to retire after 14 years with the expanded Group, both as a Non-Executive Director (NED) of Novacyt and formerly NED of Lab21, which was acquired by the Group in 2014. Ed's retirement from the Board will take effect from 31 December 2022.

James Wakefield, Chairman of Novacyt, added :

"On behalf of the Board, I would like to thank Ed for the considerable contribution, input and support that he has provided to the Group during his 14 year tenure and wish him well with his retirement."

Ed Snape, NED of Novacyt, commented:

"It has been a pleasure to have worked with so many exceptional people at Novacyt and Lab21 over the years and I would like to thank them all for their hard work and support. I look forward to watching Novacyt continue on its exciting journey to become a leading, global clinical diagnostics company in infectious diseases."

- End -

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

Numis (Joint Broker)

James Black / Freddie Barnfield / Duncan Monteith

[phone]

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

[phone]

[e-mail] ; [e-mail]

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

[phone]

[e-mail] / [e-mail]

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com

 

END

 

 

BOAUBUNRUVUURRA